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Abstract
Fibrous dysplasia has been regarded as a developmental skeletal disorder characterized by
replacement of normal bone with benign cellular fibrous connective tissue. It has now become
evident that fibrous dysplasia is a genetic disease caused by somatic activating mutation of the Gsα
subunit of G protein-coupled receptor resulting in upregulation of cAMP. This leads to defects in
differentiation of osteoblasts with subsequent production of abnormal bone in an abundant fibrous
stroma. In addition there is an increased production of IL-6 by mutated stromal fibrous dysplastic
cells that induce osteoclastic bone resorption.
Introduction
Fibrous dysplasia (FD) is a sporadic benign skeletal disor-
der that can affect one bone (monostotic form), or multi-
ple bones (polyostotic form), and the latter may form part
of the McCune-Albright syndrome (MAS) or of the Jaffe-
Lichtenstein syndrome (JLS). JLS is characterized by poly-
ostotic FD and café-au-lait pigmented skin lesions, while
MAS has the additional features of hyperfunctional endo-
crinopathies manifesting as precocious puberty, hyperthy-
roidism or acromegaly [1,2].
Gender prevalence of FD is equal. The monostotic form is
more common and affects the 20 to 30 years age group:
polyostotic FD has its onset mainly in children younger
than 10 years of age, the lesions grow with the child, sta-
bilize after puberty, and most commonly involve cranio-
facial bones, ribs, and metaphysis or diaphysis of the
proximal femur or tibia [3]. The ratio of occurrence of
polyostotic to monostotic FD is 3:7 [4,5].
Signs and symptoms of FD include bone pain, pathologi-
cal fractures and bone deformities [6]. Serum alkaline
phosphatase (ALP) is occasionally elevated, but calcium,
parathyroid hormone, 25-hydroxyvitamin D, and 1,25-
dihydroxyvitamin D levels in most cases of FD are nor-
mal. Persons with extensive polyostotic FD may have
hypophosphatemia, hyperphosphaturia and osteomala-
cia [3]. Malignant transformation is rare, and is usually
precipitated by radiation therapy [7].
The craniofacial bones are affected in about 10% of cases
of monostotic FD and in 50% to 100% of cases of polyos-
totic FD [4,8,9]. When only the cranial and facial bones
are affected by FD the term craniofacial FD is used. The
prevalence of the polyostotic craniofacial FD ranges from
71% to 91% and of the monostotic form, from 10% to
29% [8,9]. FD of the jaws affects the maxilla more fre-
quently than the mandible and affects females more fre-
quently than males [7].
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Any cranial or facial bone can be affected by FD and the
clinical associated features will depend upon the bone or
bones affected. Signs and symptoms can include facial
pain, headache, cranial asymmetry, facial deformity,
tooth displacement, and visual or auditory impairment
(figures 1 and 2) [4,8].
The aetiology of FD
FD is a genetic non-inherited condition caused by mis-
sense mutation in the gene GNAS1 on chromosome 20,
that encodes the alpha subunit of the stimulatory G pro-
tein-coupled receptor, Gsα. The activating mutations
occur post-zygotically, replacing the arginine residue
amino acid with either a cystein or a histidine amino acid.
The mutation selectively inhibits GTPase activity, result-
ing in constitutive stimulation of AMP-protein kinase A
intracellular signal transduction pathways [2,6,10-16].
The systemic manifestations of the mutated Gsα protein-
coupled receptor complex include autonomous function
in bone through parathyroid hormone receptor; in skin
through melanocyte-stimulating hormone receptor; in
ovaries through the follicle-stimulating hormone recep-
tor; and in the thyroid and the pituitary gland, through
the thyroid and growth hormone receptors respectively
[3].
FD is a somatic mosaic disorder with a broad spectrum of
phenotypic heterogeneity. The extent of the disease is
related to the stage at which the post-zygotic mutation in
Gsα had occurred, whether during embryonic develop-
ment or postnatally [13,16].
Polyostotic FD can affect bones derived from mesoderm
or neural crest, and is associated with pregastrulation
mutation. The same process associated with multiple-
organ manifestations of Gsα mutation is referred to as
McCune-Albright syndrome. The mutated pluripotential
cell develops into a mutated clone of cells affecting bones
in the case of FD, and affecting multiple organs together
with bones in the case of McCune-Albright syndrome [6].
Monostotic FD and polyostotic FD without either cranio-
facial skeletal or extraskeletal organ involvement can
develop from a post-gastrulation mutation; but since
polyostotic FD nearly always involves craniofacial bones,
it is reasonable to assume that the monostotic FD is the
only form of FD that can develop post-gastrulation [6].
Severity and extent of Gsα mutation-associated diseases
are not related to the stage of embryogenesis when the
mutation occurred, but rather are functions of survival of
mutated cells within the clone during migration, growth
and differentiation, and of the ratio of mutated to normal
cells at the affected anatomical site [6,13].
The postnatal manifestation of FD is not a reflection of the
stage of development when the mutation occurred but
indicates the time that the dynamic equilibrium between
mutated and normal osteogenic cells in the mosaic
fibrous dysplastic bone favoured the mutated cells. Possi-
ble factors influencing the dominance of mutated over
normal cells include growth factors and hormones [6],
and it is probable that there is a 'critical mass' of mutated
cells necessary for the development of FD. The burden of
mutated cells in FD frequently declines with age, owing to
imponderable suppressive influences shifting the balance
of transformed to normal cells towards predominance of
normal cells, resulting in arrest of FD [6].
The cellular portion of the abnormal bone in FD is com-
posed of a mosaic of mutated and non-mutated osteo-
Craniofacial fibrous dysplasia showing a diffuse swelling of the  right maxillary region causing facial asymmetry Figure 1
Craniofacial fibrous dysplasia showing a diffuse swell-
ing of the right maxillary region causing facial asym-
metry.
Intraoral view of case shown in figure 1 Figure 2
Intraoral view of case shown in figure 1. Note the dif-
fuse expansion of the palate and buccal bony plate of the 
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genic cells [16]. In fibrous dysplastic bone, the increased
expression of cAMP by the mutated lesional cells is asso-
ciated with abnormal osteoblast differentiation and for-
mation of defective bone [17]. Fibrous dysplastic lesions
have characteristic changes in bone matrix organization,
in expression of certain non-collagenous proteins of the
extracellular matrix, and in mineralization; and the
mutated cells within the lesion are morphologically
altered [15].
The skeletal lesions of FD
Focal lesions of FD are somatic mosaics, and the severity
and extent of the bony lesions are a function of the ratio
between the mutated cells and the normal osteoblasts;
and of the severity of cytogenic alterations and the subse-
quent functional impairment of the mutated cells [3,10].
The cellular component of the bony lesions of FD com-
prises mesenchymal cells of osteogenic lineage. There is a
variable ratio between normal osteoblasts and mutated
fibroblast-like cells. The mutated cells are poorly differen-
tiated, functionally impaired osteoblasts with an
increased proliferation rate [17], and are capable of pro-
ducing extracellular matrix and woven bone. However the
woven bone is abnormal in organization and in composi-
tion.
The bone matrix in fibrous dysplastic lesions is deficient
in osteopontin and in bone sialoprotein (BSP), compared
to normal bone. BSP is a marker of osteoblastic cell differ-
entiation and its expression is required for mineralization
[2,17]. Indeed, fibrous dysplastic bone lesions demon-
strate a deficit in mineralization that can be defined as
localized osteomalacia. The unmineralized woven bone
in long bones at sites where FD develops never matures
into lamellar bone; and the local 'normal' mineralized
bone adjacent to the lesion shows a relatively low mineral
concentration. However, in persons with FD, the bones
that are not affected by FD do not have osteomalacic
changes [14,15]. In contrast to FD of long bones, in
craniofacial FD the immature woven bone may undergo
lamellation. These differences between the mineralization
of FD of long bones and of craniofacial membranous
bones, may be owing to the fact that these two embryolog-
ically distinct types of bone are under different inductive
influences during development.
In addition to the osteomalacic changes, fibrous dysplas-
tic bone shows increased osteoclastic activity, and markers
of bone resorption may be elevated in some affected per-
sons [15]. The mutated stromal cells of FD express high
levels of IL-6 owing to the inherited cellular excess of
cAMP. The increased levels of IL-6 stimulate osteoclas-
togenesis that contributes to the bone resorption at the
site of FD [10]. Thus the fibrous dysplastic bone is charac-
terized by increased bone resorption and poor mineraliza-
tion.
FD and bone lesions caused by hyperparathyroidism are
similar in nature, and are generated by the intracellular
downstream effect of the activation of the parathyroid
hormone (PTH) G protein-coupled receptor of osteogenic
cells. While in hyperparathyroidism PTH receptor is over
stimulated by excess PTH, in FD the same receptor is
inherently active owing to the mutation in the α subunit
of the G protein [12]. The end result in both FD- and in
hyperparathyroidism-associated bony lesions is an
increase in osteoclastogenesis resulting in bone resorp-
tion. However, while hyperparathyroidism-induced bony
lesions are characterized by tunnelling bone resorption
[15], there is evidence that fibrous dysplastic lesional cells
are more sensitive and responsive to PTH stimulation
than normal osteoblasts, but tunnelling resorption is not
evident in persons with FD that do not have parathy-
roidism [15].
Radiological features and microscopic features 
of FD
The radiological features of FD are diverse and are
dependent upon the proportion of mineralized bone to
fibrous tissue in the lesion [17]. Early FD of craniofacial
bones is radiolucent with either ill defined or well defined
borders, and may be unilocular or multilocular. As the
lesions mature, the bony defects acquire a mixed radiolu-
cent/radiopaque appearance, and established FD exhibits
mottled radiopaque patterns often described as resem-
bling ground glass, orange peel or fingerprints, with ill
defined borders blending into the normal adjacent bone
(figure 3) [1,9,18].
Cropped panoramic radiograph of fibrous dysplasia of the left  mandible Figure 3
Cropped panoramic radiograph of fibrous dysplasia 
of the left mandible. Note the diffuse mottled-glass 
appearance and tooth displacement.Head & Face Medicine 2009, 5:22 http://www.head-face-med.com/content/5/1/22
Page 4 of 5
(page number not for citation purposes)
Microscopically, FD comprises irregular trabeculae of
woven bone, blending into the surrounding normal bone
(figure 4) and lying within a cellular fibrous stroma with
osteoblast progenitor cells resembling fibroblasts (figure
5) [19]. These trabeculae of woven bone have been fanci-
fully said to resemble Chinese script writing [1].
Early craniofacial FD is characterized by minimally miner-
alized deposits of woven bone with a continuum progres-
sive lamellation of the woven bone trabeculae as FD
becomes more mature (figure 6). This is in contrast to FD
lesions in long bones where mature lamellar bone is not
found [15].
Treatment of FD
There is no cure for FD, and the existing guidelines for
treatment are not universally accepted. Spontaneous reso-
lution of FD does not occur [17]. Fibrous dysplastic
lesions that are not symptomatic, that do not progress and
that do not cause deformities or functional impairment
should simply be monitored [8]. Surgical intervention is
required when important structures are in danger of com-
pression [9]. However, after surgical reduction of fibrous
dysplastic lesions, particularly in younger subjects and
when the lesions are more immature, is high (50%) [8,9],
so a conservative surgical approach will often require
more than one intervention to control the clinical signs
and symptoms [8]. As an alternative treatment, when sur-
gery is not indicated, relief of bone pain and reduction of
osteoclastic activity with partial filling of osteolytic lesions
can be achieved with intravenous bisphosphonate ther-
apy [3,17,20].
Conclusion
Fibrous dysplastic lesional cells are committed osteogenic
precursor cells with impaired capacity to differentiate into
normal functioning osteoblasts. The defects in osteoblast
differentiation are associated with Gsα mutation of both
neural crest and mesoderm-derived osteogenic cells and
may thus affect any part of the osteogenic compartment.
Poorly demarcated line of fusion between FD bone (left of  arrow) and residual bone (right of arrow) (H&E stain, ×100) Figure 4
Poorly demarcated line of fusion between FD bone 
(left of arrow) and residual bone (right of arrow) 
(H&E stain, ×100).
Fibroblast-like osteoblast progenitor cells forming a woven  bone deposit in a fibrous matrix Figure 5
Fibroblast-like osteoblast progenitor cells forming a 
woven bone deposit in a fibrous matrix. Note the 
absence of osteoblastic rimming around the woven bone 
(H&E stain, ×250).
Polarized light photomicrograph of craniofacial FD showing  lamellation of Chinese character-like trabeculae (H&E stain,  polarized light, ×150) Figure 6
Polarized light photomicrograph of craniofacial FD 
showing lamellation of Chinese character-like trabec-
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